Physician profile
Jin Sol Oh
NPI 1962842658
$15,024.58
in general payments reported to CMS, 2019-2025
24 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,325 · 2020: $1,656 · 2021: $904 · 2022: $152 · 2023: $1,330 · 2024: $3,360 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Travel and Lodging: $1,090 · Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Travel and Lodging | $1,090.36 |
| Food and Beverage | $897.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $13,695.68 | 2019-2024 | Da Vinci Surgical System |
| Davol INC. | $249.20 | 2022-2025 | Phasix Mesh |
| Covidien Lp | $141.39 | 2020 | |
| Kerecis Limited | $129.60 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Boston Scientific Corporation | $95.71 | 2024 | Rezum Generator |
| Baxter Healthcare | $88.89 | 2024 | Tisseel |
| Lemaitre Vascular, INC. | $77.98 | 2023-2024 | Artegraft Vascular Graft, Restoreflow |
| Takeda Pharmaceuticals U.S.A., INC. | $72.54 | 2022-2023 | Gattex |
| Conmed Corporation | $57.53 | 2024 | Airseal |
| Csl Behring | $55.27 | 2019-2020 | |
| Smith+Nephew, INC. | $48.48 | 2025 | Stravix Pl |
| Medical Device Business Services, INC. | $39.16 | 2024 | Linx Reflux Management System |
| Trevena, INC. | $38.57 | 2023 | Olinvyk |
| Merck Sharp & Dohme LLC | $32.92 | 2019-2023 | Keytruda, Lynparza |
| Olympus America INC. | $29.93 | 2023 | Itind System, Soltive |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $27.25 | 2019 | |
| Sumitomo Pharma America, INC. | $25.89 | 2025 | Gemtesa |
| Medtronic, INC. | $24.29 | 2025 | Dextile |
| Travere Therapeutics, INC. | $20.97 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $17.53 | 2025 | |
| Antares Pharma, INC. | $15.76 | 2025 | Xyosted |
| Procept Biorobotics Corporation | $14.13 | 2021 | |
| W. L. Gore & Associates, INC. | $13.51 | 2019 | |
| Myriad Genetic Laboratories, INC. | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jin Sol Oh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.